Pomerantz LLP is investigating claims on behalf of investors of Replimune Group, Inc. ("Replimune" or the "Company") . Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or ...
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced multiple presentations at the 2026 American ...
LofyGang resurfaces with LofyStealer disguised as Minecraft hack, exfiltrating IBANs and passwords to 24.152.36[.]241, ...
Pomerantz LLP is investigating claims on behalf of investors of Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL). Such investors are ...
The average one-year price target for Replimune Group (NasdaqGS:REPL) has been revised to $5.04 / share. This is a decrease of 59.94% from the prior estimate of $12.58 dated April 12, 2026. The price ...
First-in-Class enVVe system to be evaluated in TAVVE U.S. Pivotal TrialClinical site activation and patient enrollment expected to commence later this yearLarge unmet clinical need for approximately 3 ...
Gabriela Moreira, CEO of Quint at Informal Systems, is a research engineer specializing in programming languages and formal ...
New Delhi [India], April 30: "Innovation, Technology or Artificial Intelligence cannot replace a human being. AI poses many challenges, and we have become exceedingly technologically advanced, but it ...
Strip away the theatre — including the surreal moment when Israel’s Foreign Ministry summoned Spain’s chargé d’affaires over an Andalusian “Burning of Judas” effigy of Netanyahu stuffed with gunpowder ...
The U.S. Food and Drug Administration has appointed Katherine Szarama as the acting director of its Center for Biologics Evaluation and Research, which regulates vaccines and biologic drugs, Politico ...
Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results